Labiotech.eu

News and Trends 22 Jul 2015

Adaptimmune’s TCR Therapy Proves its Superiority over its Immuno-oncology Competitors

Adaptimmune Therapeutics, an oxford-based company focusing on the use of T-cell therapies to treat cancer, announced today that data from its Phase I/II study in patients with multiple myeloma has been published in Nature Medicine. This is the first report on TCR engineered T-cell therapy that shows durable persistence in patients! After its successful intoduction on […]

July 22, 2015 - 3 minutesmins - By Joachim Eeckhout

News and Trends 21 Jul 2015

NASDAQ-listed Biotech from Boston shops cancer-treating antibodies in Italy

A new partnering deal in the trendy field of immune-oncology. Boston-based Agenus signed a €40M deal with Italian Biotech Diatheva to get antibodies, which are targeting a glycoprotein expressed on T cell and NK cell lymphocytes to boost the immune system of patients to fight major cancer. The Boston (Lexington)-based company Agenus went on the NASDAQ […]

July 21, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 21 Jul 2015

BMS steps into the European Market with its new Lung Cancer Treatment

It’s the first major treatment for metastatic squamous non-small cell lung cancer (NSCLC) to have been approved in over a decade in Europe: Bristol-Myers Squibb’s PD-1 immune checkpoint inhibitor Nivolumab was granted with market authorization by the European Commission. The drug is the first to improve overall survival in previously-treated metastatic NSCLC. Just one month […]

July 21, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 21 Jul 2015

Genetically Modified Insects: Designed to Cause Extinction

Insects can be very dangerous creatures, spreading diseases and destroying the yield. The British biotech company Oxitec developed a unique approach to potentially wipe out some harmful populations of these tiny animals. Studies on the diamondback moth are already showing good results! Farmers around the world struggle with a serious pest caused by the diamondback moth […]

July 21, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 20 Jul 2015

InnaVirVax Raises €3.6M to Speed Up its HIV Vaccine

HIV is definitely under the spotlight today. Just after Theravectys’ announcement about its phase I/II success, InnaVirVax completed a third funding round to accelerate its Phase 2 clinical development. The first-in-class immunotherapy designed to treat HIV infections gained further support by all the historical investors in the company. Since 1987, HIV has mainly been treated with a combination of […]

July 20, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 20 Jul 2015

Theravectys’ HIV Cure on the Road to Success

Theravectys just announced positive results of its HIV drug candidate in a phase I/II study. The therapeutic vaccine using lentivirus could be the first cure available for the 35 million people currently suffering from this worldwide epidemic. Paris-based Theravectys presented detailed results from its phase I/II study at the 2015 Towards an HIV Cure Symposium in Vancouver, Canada. The trial currently enrolled 38 HIV-positive patients […]

July 20, 2015 - 3 minutesmins - By Joachim Eeckhout

News and Trends 20 Jul 2015

European Biotechs Outperform, Here is the Proof

We underwent great Biotech stories in 2014. However, was 2014 really a good year for the Biotech industry? EY released Beyond borders 2015, its 29th Biotechnology Industry Report. We summed up the most important details for you concerning the European Biotech sector. So, let’s go over a few statistics. First impression, the Biotech industry is definitely […]

July 20, 2015 - 2 minutesmins - By Joachim Eeckhout

News and Trends 20 Jul 2015

DBV raised €255M on the NASDAQ

[Update 20/07/2015] After successfully closing its Underwritten Public Offering, DBV finally raised €255M ($281,5M) on the NASDAQ. Original article from 16/07/2015: DBV Technologies is going for its second fundraising on the NASDAQ, hoping for €223M. €68.6M were already secured last week from Baker Bros. Advisors LP. The money will allow the company to stay independent all […]

July 20, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 17 Jul 2015

TC BioPharm raises €1.7M to commence treatment in UK cancer patients

TC BioPharm raised €1.7M (£1.18) to treat UK-based patients with melanoma, lung and kidney cancer. Thanks to this funding, the Phase I/II clinical studies will start as of September in several parts of the country. TC BioPharm’s lead product, ImmuniCell, uses patients’ own cells grown in culture to target a wide variety of different cancers. […]

July 17, 2015 - 1 minutemin - By Lourdes Riquelme

News and Trends 17 Jul 2015

GSK and Partners Bavarian Nordic and J&J Ebola vaccine candidates both reach Phase II

In outbreak situations such as the Ebola crisis, vaccines play an essential role that was largely needed during the 2014 health emergency, especially when the plague reached the First World. To ensure preparedness against Ebola, now and in the future, companies have been rushing to develop vaccines against this disease. GSK has come up with […]

July 17, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 17 Jul 2015

AC Immune receives Milestone Payment for Alzheimer Antibody

AC Immune received a first milestone payment from Roche’s subsidiary Genentech. The latter picked up a potential Alzheimer’s drug worth developing towards clinical trials. The collaboration began in 2012 with Genentech’s promising milestone payments amounting to more than €384M (CHF400M). Alzheimer’s disease will be one of the biggest burdens of tomorrow’s society showing a dramaticaly […]

July 17, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 16 Jul 2015

Imperial Innovations receives a €71M loan from the European Investment Bank

Imperial Innovations secured another loan facility from the European Investment Bank (EIB) to support the company’s investments in the UK biotech and life science sector. This €71.3M (£50 million) funding follows a previous €42.9M (£30 million) loan granted by the EIB in July 2013. The European Investment Bank, which last year provided €13.3Bn to enhance […]

July 16, 2015 - 2 minutesmins - By Lourdes Riquelme

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Adaptimmune’s TCR Therapy Proves its Superiority over its Immuno-oncology Competitors

NASDAQ-listed Biotech from Boston shops cancer-treating antibodies in Italy

BMS steps into the European Market with its new Lung Cancer Treatment

Genetically Modified Insects: Designed to Cause Extinction

InnaVirVax Raises €3.6M to Speed Up its HIV Vaccine

Theravectys’ HIV Cure on the Road to Success

European Biotechs Outperform, Here is the Proof

DBV raised €255M on the NASDAQ

TC BioPharm raises €1.7M to commence treatment in UK cancer patients

GSK and Partners Bavarian Nordic and J&J Ebola vaccine candidates both reach Phase II

AC Immune receives Milestone Payment for Alzheimer Antibody

Imperial Innovations receives a €71M loan from the European Investment Bank

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!